ClinicalTrials.gg
RecruitingNCT04796350Updated May 13, 2026

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

An interventional study of AGN1 LOEP treatment in Fragility Fracture, Hip Fractures and Osteoporosis, sponsored by AgNovos Healthcare, LLC. Recruiting at 66 sites in 11 countries. Open to female participants aged 65 Years to 91 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by AgNovos Healthcare, LLC · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,400
Allocation
Randomized
Ages
65 Years to 91 Years
Sex
Female
01

Study summary

A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.

Read the detailed description

This is an event driven, randomized, controlled, prospective, single blinded (non-blinded in Canada), multi-national study.

This study is designed to demonstrate that the AGN1 LOEP treatment can reduce the incidence of secondary hip fractures in subjects presenting with an index hip fracture and undergoing hip fracture repair surgery. Subjects presenting with an index fragility hip fracture who will undergo hip fracture repair will be enrolled. Subjects will be randomized 1:1 into the following two study groups:

  1. Treated Group - receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip
  2. Control Group - receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip

AGN1 LOEP is an elective procedure that will be performed immediately following hip fracture repair.

Subjects will be followed through scheduled visits conducted at 6 weeks, 6 months, and every 6 months thereafter for a minimum of 5 years.

02

Conditions studied

  • Fragility Fracture
  • Hip Fractures
  • Osteoporosis

Keywords

  • Osteoporosis
  • Hip Fracture
  • Fragility Fracture
  • LOEP
  • RESTORE
  • Local osteo-enhancement procedure
03

In context

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

This study's planned enrollment of 2,400 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.

Browse Hip Fractures studies →

Lead sponsor

AgNovos Healthcare, LLC is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 91 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a female at least 1-year post menses and at least 65 years of age and less than 92 years of age.
  2. Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.
  3. Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review):

    • Documented falls assessment indicating subject is at moderate or high risk of falls
    • Falls history (2 or more falls in the previous 12 months)
    • History of vertigo, dizziness, or postural hypotension
    • Documented T-score \< -2.5 at the hip
    • Taking more than 3 daily prescription medications
    • Visual impairment as confirmed by one of the following:

      • Subject reports difficulty seeing
      • Lack of depth perception or vision loss in one eye
      • Macular degeneration
      • Cataracts
    • Prior non-hip fragility fracture
    • Cognitive frailty as assessed by SPMSQ (mild cognitive impairment determined by SPMSQ ≤ to 4) or delirium
    • Parkinson's disease stage 3 or 4
    • 10-year hip fracture probability >15% using the FRAX® Fracture Risk Assessment Tool of the clinical site country
  4. Subject is expected to be ambulatory after the hip fracture repair procedure. "Ambulatory" is defined as a patient's ability to ambulate beyond simple transfers with or without assistive devices.
  5. is provided by the subject or the subject's LAR. Use of an LAR to obtain patient consent requires that the patient must understand and be able to participate in post operative restrictions and requirements.
  6. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented.

Exclusion criteria

Exclusion Criteria:

  1. Criterion omitted
  2. Criterion omitted
  3. Subject is currently enrolled in another interventional clinical study affecting the target hip.
  4. Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture.
  5. Subject has new fractures in addition to the index hip fracture at admission that, in the opinion of the investigator, would further compromise patient mobility, rehabilitation, or recovery.
  6. Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment.
  7. Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side.
  8. Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and/or treated for atypical femoral fractures.
  9. Criterion omitted
  10. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
  11. Criterion omitted
  12. Subject has active cancer
  13. Criterion omitted
  14. Criterion omitted
  15. Criterion omitted
  16. Criterion omitted
  17. Criterion omitted
  18. Subject has end stage renal insufficiency defined as an estimated (eGFR) \< 15 mL/min.
  19. Criterion omitted
  20. Criterion omitted
  21. Subject has moderate or severe cognitive impairment as assessed by an SPMSQ of 5 or higher.
  22. Subject has known allergies to calcium-based bone void fillers.
  23. In the judgement of the Investigator, the subject is not a good study candidate (e.g., poor mental health, or active drug or alcohol abuse issues), and or subject would not be a good candidate to undergo an ELECTIVE orthopedic surgical procedure such as a total hip arthroplasty in her current medical, physiological condition.
  24. Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
2,400 participants (estimated)

Study arms

  • Experimental
    Treated group

    Subject receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip

    Device: AGN1 LOEP treatment

  • No intervention
    Control group

    Subject receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip

Interventions

  • DeviceAGN1 LOEP treatment

    the implantation site is injected with the AGN1 implant material

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of secondary fragility hip fractures

    Comparison of incidence of secondary fragility hip fractures in the target hip among the Treated Group vs. Control Group.

    Time frame: Interim Analysis, approximately 30 Months

  2. Cumulative Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Comparison of incidence of AEs and SAEs among the Treated Group vs. Control Group.

    Time frame: Interim Analysis, approximately 30 Months

Secondary outcomes

  1. Areal bone mineral density (aBMD)

    Total hip areal bone mineral density in target hips of the Treated Group compared to the Control Group

    Time frame: 12 months and 24 months

07

Study locations

48 of 66 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The sponsor is limited in its flexibility to share data given informed consent forms. Requests for data sharing will be considered by the study sponsor on a case-by-case basis

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Apr 2027, 71 months after the start.

Of 237 interventional studies with no phase under Hip Fractures, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 57. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 12, 2021
StartActual
Apr 24, 2021
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2029
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04796350
Lead sponsor
AgNovos Healthcare, LLC
Collaborators
Avania, CMIC Co, Ltd. Japan, BioClinica, Inc., Emergent Clinical Consulting, LLC
Responsible party
Sponsor
First posted
Mar 12, 2021
Start date
Apr 24, 2021
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
May 13, 2026

Study contacts

Charles Raymond
Contact
restore@agnovos.com
240-753-6421

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion